Evidence map›Paper›PMID 42151197›Full record

ArticleScientific data2026

Proteome of Bronchial Alveolar Lavage fluid and Serum from Tuberculosis patients during drug treatment.

Luisa Maria Nieto Ramirez, Karen M Dobos, Annie Moradian, Anandi Bierman, Rao Shruti, Eric Osei, Marisa Harton, Dylan Kain, David Lewinsohn, John T Belisle and 3 more

Abstract readDataset
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Luisa Maria Nieto Ramirez *Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA.
Karen M Dobos *Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA.ORCID http://orcid.org/0000-0001-7115-8524
Annie MoradianPrecision Biomarker Laboratories, Beverly Hills, CA, USA.
Anandi BiermanSouth African Medical Research Council Centre for Tuberculosis Research, Division of Immunology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Rao ShrutiPrecision Biomarker Laboratories, Beverly Hills, CA, USA.
Eric OseiDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA.
Marisa HartonDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA.
Dylan KainDepartment of Pulmonary and Critical Care Medicine, Oregon Health and Sciences University, Portland, OR, USA.
David LewinsohnDepartment of Pulmonary and Critical Care Medicine, Oregon Health and Sciences University, Portland, OR, USA.ORCID http://orcid.org/0000-0001-9906-9494
John T BelisleDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA.
Jennifer Van EykPrecision Biomarker Laboratories, Beverly Hills, CA, USA.ORCID http://orcid.org/0000-0001-9050-148X
Gerhard WalzlSouth African Medical Research Council Centre for Tuberculosis Research, Division of Immunology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Nelita Du PlessisSouth African Medical Research Council Centre for Tuberculosis Research, Division of Immunology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. nelita@sun.ac.za.

Funding

T cell recognition of the MR1 presented microbial metabolomeR01AI147954 · NIAID · UNIVERSITY OF CHICAGO · PI ADAMS, ERIN JUNE, HILDEBRAND, WILLIAM · 2019 to 2023
$7.3M
Lung Resident, MR1-Restricted T Cells: Association with Differential Outcomes Following Exposure to M. TuberculosisR01AI134790 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LEWINSOHN, DAVID M., WALZL, GERHARD · 2018 to 2022
$3.3M
NIAID NIH HHS R01 AI134790NIAID NIH HHS R01 AI147954U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI34790U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI47954
6 · The paper itself

Abstract

People with tuberculosis (TB) undergo months of drug treatment before cure. Recent studies suggest that, even after successful treatment, TB patients may not fully clear the bacterium and be at risk for disease recurrence due to reactivation of resident bacilli. In this study, we conducted an analysis of the proteome of ten TB patients at week 1 after initiation of therapy and after twenty-five weeks of therapy, and also in 10 healthy community controls to identify dynamic and stable protein patterns in the lung and blood. We used bronchial alveolar lavage fluid (BALf) and serum from each TB patient at both time points for our analyses and identified 2,060 and 416 proteins in the BALf and serum samples, respectively, from at least 60% of the samples from each group. Six proteins shared significant trends between the two sample types. Data are available via ProteomeXchange PXD073337 for comparative studies and include a unique, paired BALf proteome data set in addition to a paired serum sample set from the same study subjects.

Indexed as

Antitubercular AgentsBronchoalveolar Lavage FluidProteomeTuberculosisHumansAntitubercular AgentsProteome

Identifiers

PMID42151197
PMCPMC13442856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.